Binge behavior regulators
Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.
1. A method of treating depression-induced binge behavior, the method comprising administering to a subject in need thereof a therapeutically effective amount of 5-methoxy-2-aminoindan or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the amount of 5-methoxy-2-aminoindan is in a range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.5 mg/ml, 0.15 mg/ml to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.
3. The method according to claim 1 , wherein the pharmaceutically acceptable salt is in a range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.5 mg/ml, 0.15 mg/ml to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.
4. The method of claim 1 , wherein the 5-methoxy-2-aminoindan or the pharmaceutically acceptable salt forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.
5. The method of claim 4 , wherein the composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.
6. The method of claim 4 , wherein the composition is a unit dosage form composition.
7. The method of claim 6 , wherein the 5-methoxy-2-aminoindan in the unit dosage form is in an amount ranging from 30 mg to 130 mg.
8. The method of claim 6 , wherein the pharmaceutically acceptable salt in the unit dosage form is in an amount ranging from 30 mg to 130 mg.
9. The method of claim 7 , wherein the amount of the 5-methoxy-2-aminoindan in the composition is 70 mg.
10. The method of claim 8 , wherein the amount of the pharmaceutically acceptable salt in the composition is 70 mg.
11. The method of claim 1 , wherein the pharmaceutically acceptable salt is administered to the subject orally.
12. The method of claim 1 , wherein the 5-methoxy-2-aminoindan is administered to the subject orally.
13. The method of claim 1 , wherein the pharmaceutically acceptable salt is an acid addition salt.
14. The method of claim 13 , wherein the acid addition salt is a hydrochloric acid addition salt, a hydrobromic acid addition salt, ascorbic acid addition salt, a besylate addition salt, a camphorsulfonic acid addition salt, a citric acid addition salt, a malic addition salt, a methanesulfonic acid addition salt, a naphthalenesulfonic acid addition salt, an oxalic acid addition salt, a phosphoric acid addition salt, a p-toluenesulfonic acid addition salt, a p-succinic acid addition salt, a p-sulfuric acid addition salt, a p-tartaric acid addition salt, or a p-trifluoroacetic acid addition salt.
15. The method of claim 6 , wherein the 5-methoxy-2-aminoindan in the unit dosage form is in an amount ranging from 30 mg to 800 mg.
16. The method of claim 15 , wherein the amount of 5-methoxy-2-aminoindan in the unit dosage form is in a range selected from 30 mg to 400 mg.
17. The method of claim 6 , wherein the pharmaceutically acceptable salt in the unit dosage form is in an amount ranging from 30 mg to 800 mg.
18. The method of claim 17 , wherein the pharmaceutically acceptable salt in the unit dosage form is in an amount ranging from 30 mg to 400 mg.
19. The method of claim 1 , wherein the depression-induced binge behavior is binge drinking.